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Improving the Prediction of Hepatocellular Carcinoma
in Cirrhotic Patients With an Arterially-Enhancing
Liver Mass
Jorge A. Marrero,1 Hero K. Hussain,2 Hahn V. Nghiem,2 Ramsey Umar,1
Robert J. Fontana,1 and Anna S. Lok1
In the United States, cirrhotic patients with known or
suspected hepatocellular carcinoma (HCC) are prioritized
for liver transplantation. Noninvasive criteria for the diag-
nosis of HCC rely on arterial enhancement of a mass. The
aim of this study was to determine whether clinical, labo-
ratory, and / or radiologic data can improve the prediction
of HCC in cirrhotic patients with an arterially-enhancing
mass. Between May 2002 and June 2003, dynamic
gadolinium-enhanced magnetic resonance imaging (MRI)
of consecutive patients with liver cirrhosis and a solid
mass were reviewed by 2 radiologists blinded to the clin-
ical diagnosis. Clinical, laboratory, and radiologic data
were recorded for all patients. A total of 94 patients with
cirrhosis and an arterially-enhancing liver mass were stud-
ied, 66 (70%) of whom had HCC. Alpha-fetoprotein
(AFP) >20 ng/mL (P  .029), tumor size >2 cm (P 
.0018), and delayed hypointensity (P  .0001) were inde-
pendent predictors of HCC. Delayed hypointensity of an
arterially-enhancing mass had a sensitivity of 89% and a
specificity of 96% for HCC. The presence of delayed
hypointensity was the only independent predictor of
HCC among patients with arterially-enhancing lesions
<2 cm (odds ratio, 6.3; 95% confidence interval [CI],
1.8-13), with a sensitivity of 80% and a specificity of 95%.
In conclusion, delayed hypointensity of an arterially-
enhancing mass was the strongest independent predictor
of HCC, regardless of the size of the lesion. If additional
studies confirm our results, the noninvasive criteria uti-
lized to make a diagnosis of HCC should be revised. (Liver
Transpl 2005;11:281–289.)
The incidence of hepatocellular carcinoma (HCC)in western countries is rising and is expected to
further increase over the next 10–15 years. Further-
more, HCC has become a leading indication for liver
transplantation in the United States due to granting of
additional model for end-stage liver disease points to
patients with known or suspected HCC.1 To date,
cytopathologic analysis remains the gold standard for a
definitive diagnosis of HCC. However, liver biopsy car-
ries a risk of bleeding and tumor seeding,2,3 and is not
always possible due to inaccessible location of the mass,
ascites, and / or coagulopathy. In addition, the tissue
sample may be insufficient for a definitive diagnosis. A
study by Torzilli et al.4 indicated that the preoperative
diagnosis of HCC based on clinical, laboratory, and
imaging data had an accuracy of 99%, suggesting that
the use of needle biopsy for a diagnosis of HCC can be
drastically reduced. The European Association for the
Study of Liver Disease HCC Conference has provided
nonhistologic criteria for a diagnosis of HCC,5 and the
United Network for Organ Sharing (UNOS) policy for
the transplantation of patients with HCC, does not
require histologic confirmation of the tumor (http://
www.unos.org/PoliciesandBylaws from July 2004).
The noninvasive criteria for the diagnosis of HCC pro-
posed by UNOS rely heavily on imaging characteristics,
in particular arterial enhancement. Using the UNOS
criteria at a single center in the United States, 33% of
patients transplanted for HCC did not have tumor after
the explant was examined and 63% of the misdiagnosed
tumors had arterially-enhancing lesions 2 cm in
diameter.6 These data suggest that arterial enhance-
ment is a consistent but nonspecific feature of HCC
and is less useful in cirrhotic patients with small (i.e.,
2 cm) masses.
Magnetic resonance imaging (MRI) has been pro-
posed as a sensitive and specific imaging modality for
the evaluation of liver masses in patients with cirrhosis.
A total of 3 studies of MRI with explant correlation
showed a sensitivity of 55, 76, and 77%, and a specific-
ity of 57, 75, and 86%, respectively, for the detection of
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HCC in patients with cirrhosis.7–9 These studies indi-
cated that the sensitivity of MRI for a diagnosis of HCC
decreases significantly with lesions 2 cm in diameter.
In the present study, 94 consecutive patients with
known cirrhosis and an enhancing liver mass were pro-
spectively evaluated with dynamic gadolinium-
enhanced MRI. The aim of this study was to determine
whether the combination of clinical, laboratory,
and / or radiologic data can improve the prediction of
HCC, especially among patients with enhancing
masses 2 cm in diameter.
Patients and Methods
Study Population
Between May 2002 and June 2003, consecutive patients with
cirrhosis and a suspected liver mass who underwent MRI for
further evaluation were included. The study was approved by the
Institutional Review Board of the University of Michigan. The
diagnosis of cirrhosis was made by histology (n  67) or by the
presence of clinical, laboratory, and / or ultrasound features of
portal hypertension (n  39).10 These patients were enrolled
from the Liver Clinics at the University of Michigan Medical
Center. The indications for MRI included: an elevated (20
ng/mL) alpha fetoprotein (AFP) level; suggestion of a mass on
ultrasound or a computed tomography scan without arterial
phase; or unexplained symptoms (such as abdominal pain,
increased ascites, jaundice, or weight loss). The etiology of liver
disease was determined as previously described.11 Patient demo-
graphics, cause of cirrhosis, presence of ascites or hepatic enceph-
alopathy, serum levels of aspartate aminotransferase, alanine ami-
notransferase, total bilirubin, alkaline phosphatase, albumin,
creatinine, AFP, international normalized ratio, model for end-
stage liver disease score, Child-Turcotte-Pugh score, white blood
cell count, and platelet count were obtained.
MRI Technique
All studies were performed on a 1.5-Tesla scanner (Signa;
General Electric Medical Systems, Milwaukee, WI), and
included the following sequences: axial longitudinal relax-
ation time–weighted, dual-echo gradient recalled-echo; axial
transverse relaxation time–weighted fat-suppressed fast-re-
covery fast spin-echo; and dynamic gadolinium-enhanced
imaging with a 3-dimensional spoiled gradient recalled-echo
sequence.12 This sequence was acquired precontrast, and fol-
lowing the injection of 20-cc gadopentetate dimeglumine
(Magnevist; Berlex Laboratories, Wayne, NJ) via a power
injector in the arterial-dominant, portal-venous, and equilib-
rium (2-minute delayed) phases of enhancement, followed by
a delayed acquisition at 5 minutes postgadolinium.
MRI Data
The magnetic resonance images were reviewed by 2 radiolo-
gists (H.K.H. and H.V.N.) with expertise in hepatic imaging,
prior to the actual knowledge of the etiology of the liver mass.
The radiologists reviewed the images independently in the 1st
1 of 3 of the cases, and simultaneously with the final opinion
rendered by consensus in the remaining 2 of 3 of the cases.
The purpose of the independent review was to obtain a mea-
sure of agreement between readers. While aware of the diag-
nosis of cirrhosis but blinded to the remainder of the patient’s
clinical data, the 2 radiologists were asked to evaluate the
imaging studies for the presence of an arterially-enhancing
mass, including homogeneously-, heterogeneously-, and ring-
enhancing lesions. The number, size, location, signal charac-
teristics, lesion hypointensity relative to surrounding liver in
the portal-venous, 2- or 5-minute postgadolinium delayed-
phases, and the presence of vascular invasion was recorded for
each case. Finally, the radiologists were asked to provide a
global consensus on the probability that the lesion is HCC by
assigning a high or low probability based on the above char-
acteristics and their overall impression.
The radiologists used standard MRI features to character-
ize focal arterially-enhancing lesions in patients with cirrho-
sis.7,13–16 Arterially-enhancing nodules were classified as 1 of
4 lesions: HCC included all arterially enhancing lesions 2
cm regardless of their other imaging features, and all arteri-
ally-enhancing lesions with transverse relaxation time–hyper-
intensity and / or delayed hypointensity regardless of their
size; dysplastic nodule included 2-cm arterially-enhancing
lesions with hyperintense longitudinal relaxation time signal,
no transverse relaxation time hyperintensity, and no delayed
hypointensity compared to the rest of the liver parenchyma;
nonspecific enhancing nodules (NSEN) included 2-cm
arterially-enhancing lesions with no corresponding signal
changes on any of the other imaging sequences; and heman-
giomas, based on a well-defined lesion with low longitudinal
relaxation time and very high transverse relaxation time signal
intensity compared to liver parenchyma, and one of 3
enhancement patterns: early uniform enhancement and
delayed contrast retention; early peripheral nodular enhance-
ment with centripetal progression to complete filling and
delayed contrast retention; and early peripheral nodular
enhancement with centripetal progression to incomplete fill-
ing and delayed contrast retention with nonenhancing central
scar.
Verification
The final diagnosis of HCC and regenerative and dysplastic
nodules was determined by histologic examination of the
lesion of interest seen on MRI that led to the interpretation
rendered by the radiologists. Hemangioma was verified by
typical imaging features and NSEN by follow-up imaging.
Patients with HCC were staged according to the UNOS-
modified Tumor Node Metastasis staging system. Patients
considered to have NSEN had a minimum of 3 (mean, 4  2;
median, 4; range, 3-9) MRI examinations over a mean fol-
low-up of 26  12 months (median, 25 months; range,
13-34) with no change in the number, size, and imaging
features of the lesions, or the AFP value.
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Statistical Analysis
Log transformation was used for AFP to account for skewness.
Kappa statistics was used to determine the level of agreement
between the 2 radiologists for the cases read independently
(with regard to tumor size, number of lesions, presence of
arterial enhancement, signal characteristics, and delayed
hypointensity). We performed a per-patient analysis in which
the final diagnosis of the main lesion seen on MRI, and later
verified by pathology or imaging follow-up, was the main
diagnosis. Pearson correlation was used to correlate the con-
sensus diagnosis of the radiologists to the actual diagnosis of
the liver mass. A 1-way analysis of variance was used to deter-
mine differences in continuous variables among the various
diagnoses of liver masses. The Wilcoxon test was used for
model for end-stage liver disease score and tumor size. Fisher’s
exact test was used to determine differences among categoric
variables.
Univariate analysis was performed to identify demo-
graphic, laboratory, clinical, and radiologic correlates of
HCC. The laboratory and clinical criteria included etiology of
liver disease, albumin, creatinine, total bilirubin, AFP, inter-
national normalized ratio, model for end-stage liver disease
score, Child-Turcotte-Pugh score, white blood cell count,
and platelet count. The radiologic criteria examined were the
presence of arterial enhancement, delayed hypointensity,
number of lesions, largest diameter of the main lesion, and
portal vein thrombosis. Variables with P values .10 in the
univariate analysis were then subjected to multivariate analy-
sis by forward logistic regression to identify independent fac-
tors associated with HCC. The adjusted odds ratio and its
confidence interval were obtained from the final model. A
2-tailed P value of .05 was used to determine statistical




During the study period, 106 patients with cirrhosis
and a suspected liver mass underwent MRI. A total of
12 patients were excluded from the analysis; 8 had no
visible mass on MRI and 4 had simple hepatic cysts.
The 8 patients in whom no mass was identified have
been followed for a mean of 18.3 months (range, 14-29
months) and have undergone a mean of 2.1  .7 MRI
examinations with no evidence of an enhancing mass.
The remaining 94 patients form the basis of this study.
Demographics, etiology of underlying liver disease, and
laboratory values at presentation for the patients who
had solid arterially-enhancing liver mass(es) on MRI are
listed in Table 1.
Liver Masses
A total of 65 (69%) patients had a diagnosis of HCC, 1
(1%) had a regenerative nodule, and 3 (3%) had dys-
plastic nodules based on histologic analysis. A total of
20 (21%) patients were diagnosed with nonspecific
enhancing nodules for which histology was not possible
due to the small size of the nodules; all had follow-up
imaging showing no change in number or size of the
lesions over a period of 13–34 months. A total of 4 of
the 65 patients with HCC were initially considered to
have nonspecific enhancing nodules, but interval
growth of the nodules on repeat MRI after 6 months led
to biopsies that revealed HCC. Delayed-phase hypoin-
tensity was not present on the initial MRI, but became
apparent during follow-up imaging when HCC was
diagnosed. A total of 5 patients (4%) had hemangiomas
based on typical MRI features. Figure 1 shows the algo-
rithm of how the main liver mass diagnosis was
achieved.
Radiologic Characteristics of the Liver Masses
An average of 2.6 liver masses per patient (range, 1-6)
and a mean maximal diameter of 3.6 cm (range, .5-15)
were found. There were 26 (28%) patients with lesions
2 cm. A total of 71 (76%) patients had unilobar
masses. A total of 60 (64%) had delayed hypointensity
of the arterially-enhancing mass, and 5 (5%) had portal
vein thrombosis. The imaging characteristics of the
masses according to the diagnoses are shown in Table 2.
The 2 radiologists had excellent agreement with regards
to the probability of HCC and radiologic characteris-
tics, with a kappa value of .837 (95% confidence inter-
val [CI], .77-.90). Furthermore, there was excellent cor-
relation between the radiologists’ consensus diagnosis
and the final pathologic diagnosis of HCC (correlation
coefficient, .64; 95% CI, .78-.89; P  .001). Examples
of a patient with a HCC and a nonspecific enhancing
nodule are shown in Figures 2 and 3, respectively.
A total of 23 patients were placed on the liver trans-
plant waiting list. A total of 7 patients had suspected
HCC (1 had an AFP value 200 with an arterially-
enhancing lesion 2 cm; 3 had an arterially-enhancing
lesion 2 cm; 3 had a suspicious lesion that was treated
with radiofrequency ablation prior to transplant), and
16 had a histology-confirmed HCC. MRI detected 39
nodules (maximal diameter, 2.6  .5) in these patients,
while 34 (maximal diameter, 2.9  1.4) nodules were
detected at the time of explant examination (P  .405
for difference in number of nodules; P  .32 for differ-
ence in diameter). Of the 34 nodules identified by
explant examination, 1 was a high-grade dysplastic nod-
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ule (1 patient), 1 was a regenerative nodule (1 patient),
and 32 (21 patients) were HCC on explant examina-
tion. The patient with a regenerative nodule had an
enlarging mass from 8 mm (initially classified as a non-
specific enhancing nodule) to 2.0 cm by MRI over a
12-month period, and the lesion had homogeneous
arterial enhancement without delayed hypointensity.
Of the 37 nodules seen on MRI in the HCC patients,
33 had delayed hypointensity (21 patients transplanted
for HCC had arterial enhancement in the main nodule
and 20 had delayed hypointensity).
Predictors of HCC
In the univariate analysis, age 50 years, AFP 20
ng/mL, model for end-stage liver disease (MELD)
score 10, size 2 cm, and the presence of delayed
hypointensity of an arterially-enhancing mass were
predictors of HCC. In the logistic regression model,
AFP 20 ng/mL (P  .029), tumor size 2 cm (P 
.0018), and delayed hypointensity of an arterially-
enhancing mass (P  .0001) were independent pre-
dictors of HCC (Table 3). The presence of delayed
hypointensity of an arterially-enhancing mass had a
sensitivity of 89% (59 / 65 patients with HCC) and
a specificity of 96% (1 – [1 / 29] without HCC) in
predicting a diagnosis of HCC.
Table 1. Comparison of Cirrhotic Patients With HCC Vs. Benign Liver Masses*
HCC (n  65)
NSEN
(n  20) DN (n  3) RN (n  1)
Hemangioma
(n  5) All (n  94)
Age (years) 58  10† 53  8 45  7 53 52  9 56  11
Gender (M:F) 45 : 20 13 : 7 2 : 1 1 : 0 4 : 1 65 : 29
Ethnicity (NHW:AA:As:H) 46 : 9 : 5 : 5 16 : 3 : 0 : 1 2 : 0 : 0 : 1 1 : 0 : 0 : 0 3 : 1 : 0 : 1 68 : 13 : 5 : 8
Etiology n (%)
HCV 46 (71) 10 (50) 2 (67) 1 (100) 2 (40) 61 (65)
HBV 3 (5) 4 (19) 1 (33) 0 2 (40) 10 (11)
Cryptogenic 12 (18) 3 (15) 0 0 0 15 (16)
Alcohol 4 (6) 2 (12) 0 0 1 (20) 7 (7)
PBC 0 1 (4) 0 0 0 1 (1)
Indication n (%)
AFP  20 ng/mL 21 (31) 7 (33) 1 (33) 0 0 29 (31)
Abnormal US/CT 41 (64) 13 (67) 2 (67) 1 (100) 5 (100) 62 (66)
Symptoms 3 (5) 0 0 0 0 3 (3)
AFP (median) ng/mL n (%) 34† 13.3 98.8 56 2.3 21.2
20 26 (39) 13 (67) 1 (33) 0 5 (100) 45 (48)
20–200 21 (33) 7 (33) 2 (67) 1 (100) 0 31 (33)
200 18 (28) 0 0 0 0 18 (19)
MELD score 11  4‡ 9  2 8  2 9 7  0.2 9.4  3.7
CTP score 7.1  1 6.9  1 7.2  1.4 8 6.3  0.7 7  2
Total bilirubin (mg/dL) 2.4  2 1.1  .6 1.2  .6 1.8 .8  .3 1.95  1.3
Platelet (k/mm3) 112  52 114  61 106  48 113 118  46 115  41
Listed for OLT n (%) 21 (31) 0 1 (33) 1 (100) 0 23 (24)
Staging 5 / 16 / 27 / 18 NA NA NA NA NA
Abbreviations: HCC, hepatocellular carcinoma; NSEN, non-specific enhancing nodule; DN, dysplastic nodule; RN, regenerative
nodule; NHW, non-Hispanic white; AA, African American; As, Asian; H, Hispanic; HCV, hepatitis C; HBV, hepatitis B; PBC, primary
biliary cirrhosis; US, ultrasound; CT, computed tomography; MELD, model for endstage liver disease; CTP, Child-Turcotte-Pugh
score; OLT, orthotopic liver transplant.
*Staging is the UNOS TNM system.
†P  .005 HCC vs. DN, NSEN, Hemangioma.
‡P  .006 HCC vs. DN, NSEN, Hemangioma.
Figure 1. Algorithm indicating how patients with cirrho-
sis and a liver mass were evaluated.
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Table 4 compares the clinical and radiologic charac-
teristics of the patients with liver masses 2 or 2 cm.
A total of 5 patients with HCC had lesions 2 cm in
diameter. All 5 HCC patients with arterially-enhancing
lesions 2 cm had delayed hypointensity, but only 1 of
21 (5%) patients with benign arterially-enhancing liver
mass had delayed hypointensity (P  .001). The uni-
variate analysis showed that age 50 years, AFP  20
ng/mL, and delayed hypointensity were associated with
HCC lesions 2 cm. However, the presence of delayed
hypointensity was the only independent predictor of
HCC among patients with HCC and lesions 2 cm
(odds ratio, 6.3; 95% CI, 1.8-13). For arterially-
enhancing lesions 2 cm, the presence of delayed
hypointensity had a sensitivity of 80% (4 / 5 in patients
with HCC) and a specificity of 95% (1 – [1 / 21] in
patients without HCC) for the diagnosis of HCC.
Discussion
In this prospective study of 94 cirrhotic patients, we
found that delayed hypointensity of an arterially
enhancing lesion was the most important independent
predictor for a diagnosis of HCC regardless of the
tumor size. Arterial enhancement (vascularity) is con-
sidered an essential characteristic of HCC,17,18 and is
used as the only radiologic feature for noninvasive diag-
nosis of HCC by UNOS. However, arterial enhance-
ment is a nonspecific feature, and may be seen in other
benign lesions such as hemangiomas (type 1), focal
nodular hyperplasia, hepatic adenoma, dysplastic nod-
ules, and, rarely, regenerative nodules.16 Furthermore,
Figure 2. MR imaging of HCC in a cirrhotic patient. Axial
dynamic magnetic resonance images through the liver in the
arterial-phase (A), and at 2 minutes following gadolinium injec-
tion(B).There is a2-cmarterial-enhancing lesion(arrow) in the
right lobe, which becomes hypointense (arrow) to the liver in
the delayed phase. Biopsy showed the lesion to be HCC. Note
the pseudocapsule (arrowheads) around the lesion on the
2-minute delayed postgadolinium image.
Table 2. Radiological Characteristics of the Liver Masses*
HCC (n  65) NSEN (n  20) RN (n  1) DN (n  3) Hemangioma (n  5) All (n  94)
No. of mass 2.5  1.4 2.6  1.8 1 1.8  1.3 2  2.6 2.6  1.6
n (%) 1 21 (33) 11 (55) 3 (100) 2 (40) 36 (38)
n (%) 2 15 (23) 4 (20) 0 1 (20) 20 (18)
n (%) 3 29 (44) 5 (25) 0 2 (40) 36 (38)
Size (cm) 4.3  3† 1.1  0.2 2.0 2.2  1.3 4.8  7 3.6  3
n (%) 2 5 (8) 20 (100) 0 1 (33) 0 26 (28)
n (%) 2 60 (92) 0 1 (100) 2 (6) 5 (60) 68 (72)
Location (R:L:B) 39 : 10 : 16 11 : 4 : 5 1 : 0 : 0 3 : 0 : 0 2 : 1 : 2 56 : 15 : 23
Arterial enhancement n (%) 65 (100) 20 (100) 1 (100) 3 (100) 5 (100) 94 (100)
Delayed hypointensity n (%) 59 (89)‡ 1 (5) 0 0 0 60 (64)
Portal vein thrombosis n (%) 5 (8)‡ 0 0 0 0 5 (5)
Abbreviations: HCC, hepatocellular carcinoma; NSEN, non-specific enhancing nodule; RN, regenerative nodule; DN, dysplastic
nodule; R, right; L, left; B, bilobar.
*Data presented as mean  SD unless indicated otherwise.
†P  .001 HCC vs. DN, NSEN.
‡P  .001 HCC vs. DN, NSEN, and Hemangioma.
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vascular abnormalities commonly seen in cirrhotic liv-
ers, such as nontumorous arterioportal shunts, also
enhance in the arterial phase and may mimic HCC.15
Longitudinal relaxation time and transverse relaxation
time signal characteristics may help distinguish some of
these lesions, but are not always helpful.19 A review by
UNOS of 666 patients with HCC in whom the explant
pathology report was available showed that 146 (22%)
patients had no tumor on explant examination, and 68
(10%) had no nodule or evidence of HCC.20 The reli-
ance on arterial enhancement alone led to a significant
number of patients receiving higher priority for trans-
plant than was necessary. In our study, arterial enhance-
ment was present in all patients with HCC and cir-
rhotic patients with other liver masses. By contrast,
delayed hypointensity of the arterially enhancing mass
was present in 89% of the patients with HCC and only
5% of patients with other arterially-enhancing liver
masses.
The exact reason why HCC lesions become hypoin-
tense compared to surrounding liver parenchyma on
delayed postgadolinium imaging is unknown. The total
number of intranodular arteries (preexisting hepatic
arteries and neovascularized arteries) is often greater in
HCC nodules than it is in the surrounding nonneoplas-
tic hepatic parenchyma.21,22 It is possible, therefore,
that early venous drainage (washout) via neovascularity
is the cause for delayed hypointensity. It is also possible
that there is no early venous drainage but lesions appear
relatively hypointense compared to surrounding
fibrotic parenchyma, which retains contrast and
appears hyperintense on delayed imaging, or that the
lesion does not have portal venous supply and appears
hypointense relative to the surrounding liver.23 We
avoided the term “washout” and used delayed hypoin-
tensity instead, since gadolinium washout may not be
the only cause for lesion hypointensity. Moreover, we
did not quantitatively evaluate for gadolinium washout;
we only qualitatively compared the lesion signal inten-
sity relative to that of surrounding parenchyma.
The diagnosis of a solid liver mass in patients with
cirrhosis is a clinical challenge for radiologists and cli-
Figure 3. A 1.5  1.6 cm arterially-enhancing nodule (arrows) remains stable between August 2001 and February 2004.
The lesion does not show hypointensity (arrows) on delayed postgadolinium imaging. Note that the lesion is better seen
on the delayed image of 2004. The patient underwent 6 scans between the dates mentioned above. Due to its stability, this
lesion was labeled as a NSEN.
Table 3. Independent Predictors of HCC
Variable OR (95% CI) P Value
AFP  20 ng/mL 11.7 (2.3–30.7) .02
Size  2 cm 27.9 (3.5–36) .001
Delayed-hypointensity* 61 (3.8–73) .0001
*Of an arterially enhancing mass.
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nicians. Only 1 other study has evaluated radiologic and
clinical characteristics as predictors of HCC.24 The
authors found that the number of lesions (odds ratio,
1.5; 95% CI, 1.03-2.31), AFP level (odds ratio, 3.2;
95% CI, .92-9.86), and delayed hypointensity
(described as venous washout) (odds ratio, 9.2; 95% CI,
1.89-45) were found to be the most important predic-
tors of HCC. However, that study did not include
cirrhotic patients with benign liver masses as controls,
the data was not stratified according to tumor size, and
the imaging characteristics were based on retrospective
review of radiology reports. In our study, cirrhotic
patients with benign liver masses were also included,
the images were prospectively read by 2 radiologists
who were blinded to clinical data and final diagnosis,
and a broader range of clinical and laboratory values
were analyzed.
Correct interpretation of liver masses in patients
with cirrhosis can be difficult due to the underlying
nodularity, the dual blood supply, and the hemody-
namic disturbances associated with cirrhosis.25 Hepatic
lesions 2 cm in size that enhance in the arterial phase
are even more problematic; some studies found that less
than 20% of these lesions turn out to be HCCs.26,27 We
showed that only 19% (5 / 26) of arterially-enhancing
lesions 2 cm in diameter were HCC. We also showed
that the presence of delayed hypointensity in arterially-
enhancing nodules 2 cm was predictive of HCC, with
a sensitivity of 80% and specificity of 95%. In addition,
4 patients were initially classified as having an NSEN
that on subsequent MRI showed interval growth and
delayed hypointensity, leading to the diagnosis of
HCC. Although we used specific criteria to classify
arterially-enhancing lesions into NSEN, dysplastic
nodule, and HCC, there is overlap in the signal charac-
teristics of these lesions, and the purpose of the NSEN
classification was to ensure imaging follow-up of these
small arterially-enhancing lesions 2 cm, which are
difficult to visualize and biopsy with ultrasound. Thus,
for patients with arterially-enhancing nodules 2 cm,
MRI should be repeated in 6 months to determine
interval growth and imaging characteristics in the
delayed phase of the suspected nodule.
We acknowledge that there are several limitations
with this study. First, our study involved 2 academic
radiologists with an interest in hepatic MRI, who have
Table 4. Comparison of Patients With Lesions  and  2 cm
Variable 2 cm (n  67) 2 cm (n  27) P Value
Age 58  10 52  8 .005
Gender (M:F) 47 : 20 18 : 9 .496
Race (NHW:AA:As:H) 48 : 9 : 4 : 6 20 : 4 : 1 : 2 .629
Etiology (HCV:HBV:Crypto:Alc) 44 : 7 : 10 : 5 17 : 3 : 5 : 2 .643
AST 94  22 88  27 .452
ALT 73  18 67  25 .395
Bilirubin (ng/mL) 1.9  2 1.3  0.7 .104
MELD 10.2  4 9.4  2 .108
CTP 7.2  1.4 6.8  1.3 .243
Platelet 113  21 111  34 .121
AFP (ng/mL) n (%) 2941  12859 51.6  139 .006
20 ng/mL 26 (38) 17 (65)
20 ng/mL 39 (57) 9 (35)
Lesion number 2.5  1.4 2.3  1.8 .916
Arterial enhancement n (%) 66 (97) 25 (96) .229
Delayed hypointensity n (%) 54 (81) 6 (23) .0001
Portal vein thrombosis n (%) 5 (8) 0 0.02






Abbreviations: NHW, non-Hispanic white; AA, African American; As, Asian; H, Hispanic; HCV, hepatitis C; HBV, hepatitis B; Crypto,
cryptogenic; Alc, alcohol; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MELD, model of endstage liver disease; CTP,
Child-Turcotte-Pugh score; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; DN, dysplastic nodule; RN, regenerative nodule;
NSEN, non-specific enhancing nodule.
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worked together for several years so our results may not
be generalizable to other centers. Second, histologic
diagnosis was not available for all patients classified as
nonspecific enhancing nodules because of the technical
difficulties of performing guided biopsies on such small
lesions. Nonetheless, all patients had at least 3 repeat
MRI examinations and were followed for a median of
25 months with no change in the number, size, or
imaging characteristics of the lesions, making it very
unlikely that these nodules were HCC. Recent reports
indicate that nodules 2 cm in patients with cirrhosis
undergoing liver transplantation were common, and
pathologic examination revealed that the majority were
nondysplastic nodules28 or showed no growth over
time.29 It is possible that most of the nonspecific
enhancing nodules are regenerative nodules. Finally, we
do not have explant examination in all our patients in
order to do a lesion-by-lesion analysis. However, in the
23 patients who underwent liver transplantation there
was excellent correlation between MRI and explant
examination with regard to the number of nodules and
the maximal diameter of the largest lesion, and the
majority of the nodules were HCC.
In summary, our prospective study of patients
with cirrhosis and a liver mass showed for the 1st
time that delayed hypointensity of an arterially-
enhancing mass was the strongest independent pre-
dictor of HCC, regardless of the size of the lesion.
The only clinical or laboratory parameter that was an
important independent predictor of HCC was an
AFP 20 ng/mL in nodules 2 cm. However, none
of the other laboratory, clinical, or demographic data
were important predictors of HCC. Our data showed
that not all arterially-enhancing masses in patients
with cirrhosis are due to HCC. Further studies in a
larger population of patients and in other centers
should be performed to validate our results. Our
findings may have important implications in defin-
ing noninvasive criteria for diagnosis of HCC and in
reducing unnecessary liver transplants in patients
with compensated cirrhosis and benign liver masses.
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